Asbestosis other diagnostic studies

Revision as of 19:23, 21 September 2011 by WikiBot (talk | contribs)
Jump to navigation Jump to search

Asbestosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Asbestosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Asbestosis other diagnostic studies On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Asbestosis other diagnostic studies

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Asbestosis other diagnostic studies

CDC on Asbestosis other diagnostic studies

Asbestosis other diagnostic studies in the news

Blogs on Asbestosis other diagnostic studies

Directions to Hospitals Treating Asbestosis

Risk calculators and risk factors for Asbestosis other diagnostic studies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Kim-Son H. Nguyen, M.D., M.P.A., Beth Israel Deaconess Medical Center, Harvard Medical School, Boston MA, Cafer Zorkun, M.D., Ph.D. [2]

Overview

Pulmonary function test

Pulmonary function tests are not diagnostic, but provide a measure of pulmonary function.

  • Most patients demonstrate a restrictive pattern with reduced lung volumes, particularly with reduced vital capacity and reduced total lung capacity, and reduced pulmonary compliance.
  • Reductions in diffusing capacity are common.
  • Some patients may show obstructive patterns, but rarely without associated tobacco exposure. Airflow limitation in these patients may be due to inflammation of large airways, resulting from asbestos deposition along the respiratory bronchioles.
  • Exudative pleural effusions may develop. These usually occur within 15 years of exposure. These may resolve spontaneously, and may leave visceral pleural thickening and blunting of the costophrenic angle, and can even impair pulmonary function in some cases.
  • Hyaline plaques may form on the parietal pleura, and may calcify. These may develop after less exposure than required for asbestosis, and are therefore more common, occurring in up to 50% of patients with asbestos exposure.

Biopsy

Bronchoalveolar lavage or biopsy may be necessary for diagnosis in some cases.

  • Path shows coated or uncoated asbestos fibers in association with pulmonary fibrosis
  • Asbestos bodies are asbestos fibers surrounded by a coating of iron and protein. Other fibers such as talc, glass, carbon, etc, may also be coated in such a manner, producing “ferruginous bodies”. Electron, but not light, microscopy can differentiate the central fiber.
  • Quantity of asbestos fibers correlates with the degree of fibrosis.

References


Template:WikiDoc Sources